Our mission is opening a digital front door to a new kind of healthcare system, one that provides greater access to high quality, convenient and affordable care. No matter who a person is, where they come from, what they look like, or if they have insurance or not—Hims & Hers connects consumers with licensed medical professionals and enables everyone to seek health and wellness care.

HIMS

Andrew Dudum

Chief Executive Officer

Melissa Baird

Chief Operating Officer

Soleil Boughton

Chief Legal Officer and Corporate Secretary

Yemi Okupe

Chief Financial Officer

Chief Executive Officer And Board Of Director

Alex Bard

Board Of Director

Dr. Toby Cosgrove

M.D. Board Of Director

Kirsten Green

Jules Maltz

David Wells

Lynne Chou O’keefe

Andrea Perez

Ambar Bhattacharyya

Dr. Patrick Carroll

About HIMS

Últimas noticias sobre Hims & Hers Health (NYSE:HIMS) Bolsa

HIMS & HERS HEALTH INC

Hims & Hers Health

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Hims & Hers

News

Movers

Hims & Hers Health, Inc. Class A Common Stock

Las acciones de HIMS caen tras la prohibición de la FDA sobre versiones elaboradas de semaglutide, clave para su negocio de pérdida de peso.

Hims &amp; Hers Health cae tras la prohibición del semaglutide por la FDA en medicamentos elaborados

Hims & Hers Health Inc

Wedbush analyst Daniel Ives maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $100 to $85.

Price Target

Analyst Ratings

DOCU

Wedbush Maintains Neutral on Docusign, Lowers Price Target to $85

Trading Ideas

BDMD

Baird Medical Shares Halted On Circuit Breaker To The Downside, Stock Now Down 6.18%

Nuveen Insured California Premium Fund Ii

Northann Shares Halted On Circuit Breaker To The Downside, Stock Now Down 41.5%

Alphawave Semi&nbsp;on Thursday announced the&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">successful&nbsp;tape out</a> of one of UCIe IP subsystem on Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) 2-nm process, supporting 36G die-to-die data rates.
The solution fully integrates with&nbsp;Taiwan Semiconductor&#8217;s Chip-on-Wafer-on-Substrate (CoWoS)&nbsp;advanced packaging technology, unlocking bandwidth density and scalability for <a target="_blank" href="https://www.businesswire.com/news/home/20250605712350/en/Alphawave-Semi-Tapes-Out-Breakthrough-36G-UCIe-IP-on-TSMC-2nm-Unlocking-Foundational-AI-Platform-IP-on-Nanosheet-Processes" rel="noreferrer noopener">advanced chiplet architectures</a>.
This milestone builds on the&nbsp;recent release&nbsp;of the Alphawave Semi AI Platform,&nbsp;proving readiness to support the future of disaggregated SoCs&nbsp;and scale-up infrastructure for hyperscale AI and HPC workloads.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45801113/keysight-synopsys-team-up-to-fast-track-rf-migration-to-taiwan-semis-n4p-process" target="_blank" rel="noreferrer noopener">Keysight, Synopsys Team Up To Fast-Track RF Migration To Taiwan Semi&#8217;s N4P Process</a>
Alphawave Semi is advancing key ecosystem collaborations to enable technologies, leveraging&nbsp;D2D-based open chiplet interoperability&nbsp;to drive a broader AI connectivity platform for the industry.
Intel Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) has tapped <a target="_blank" href="https://www.benzinga.com/media/25/04/44962945/intel-taps-taiwan-semiconductor-for-advanced-2nm-process-for-ai-powered-chips-report" rel="noreferrer noopener">its long-term supplier</a>,&nbsp;Taiwan Semiconductor, for its&nbsp;advanced 2-nm process.
Intel and Taiwan Semiconductor are collaborating on a 2nm product to manufacture the compute tile for Intel&#8217;s next-gen Nova Lake PC processors, which are expected in 2026.
Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is already a client of Taiwan Semiconductor&#8217;s 2-nm process.
According to Ming-Chi Kuo, Apple Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)&nbsp;upcoming&nbsp;iPhone 18&nbsp;lineup <a target="_blank" href="https://www.benzinga.com/25/03/44453733/apples-iphone-18-to-get-massive-boost-with-2nm-a20-chiptsmcs-yields-surge-past-70-says-top-analyst" rel="noreferrer noopener">will likely feature</a>&nbsp;Taiwan Semiconductor&#8217;s 2-nm A20 chip.
Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45466444/to-serve-exploding-ai-chip-demand-taiwan-semiconductor-plans-9-advanced-factories" rel="noreferrer noopener">plans to build</a> five wafer fabs in Kaohsiung to produce chips using 2-nm and A16 technology. It expects its 2-nm technology to start commercializing in the second half of 2025 at two new fabs in Hsinchu and Kaohsiung.
The company will also add an advanced chip packaging facility using chip-on-wafer-on-substrate (CoWoS) technology.
Price Action: TSM stock is up 0.24% to $203.83 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45748492/taiwan-semiconductors-japan-chip-factory-faces-delays-while-us-expansion-takes-priority" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor&#8217;s Japan Chip Factory Faces Delays, While US Expansion Takes Priority</a></li>
</ul>
Photo by wakamatsu via Shutterstock

Tech

AAPL

INTC

Taiwan Semiconductor Powers Alphawave's 2nm Chip Breakthrough For Faster AI And HPC Connectivity

The Generation Essentials Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 30.5%

Keybanc analyst Jackson Ader initiates coverage on Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Sector Weight rating.

Initiation

FSLY

Keybanc Initiates Coverage On Fastly with Sector Weight Rating

Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) posted better-than-expected first-quarter results after <a href="https://www.benzinga.com/quote/RBRK/earnings">Thursday&#8217;s closing bell</a>.
Rubrik reported quarterly losses of 15 cents per share, which beat the analyst consensus estimate of losses of 32 cents. Quarterly revenue came in at $278.48 million, which beat the Street estimate of $260.35 million.
"Our outstanding first-quarter results not only surpassed all guided metrics but also underscore the power of our focused innovation and execution. We are winning the cyber resilience market, and I believe that our opportunity is bigger than ever," said Bipul Sinha, Rubrik's CEO.
Rubrik raised its fiscal 2026 adjusted EPS guidance to a range of losses of $1.02 to losses of 96 cents, versus the estimate of losses of $1.15. The company raised its fiscal revenue outlook to between $1.18 billion and $1.19 billion, versus the $1.16 billion estimate.
Rubrik shares gained 2.6% to trade at $100.93 on Friday.
These analysts made changes to their price targets on Rubrik following earnings announcement.
<ul class="wp-block-list">
<li>Rosenblatt analyst Blair Abernethy maintained Rubrik with a Buy rating and raised the price target from $82 to $110.</li>
<li>Keybanc analyst Eric Heath maintained the stock with an Overweight rating and boosted the price target from $98 to $113.</li>
</ul>
Considering buying RBRK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-1024x585.png" alt="" class="wp-image-941256" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06093408/image-100.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

RBRK

These Analysts Boost Their Forecasts On Rubrik After Better-Than-Expected Q1 Results

WIIM

VERO

VERO stock has given up its prior loss. Venus Concept shares were trading lower after the company announced it entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group.

Scotiabank analyst Louise Chen upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sector Perform to Sector Outperform and maintains the price target from $80 to $80.

Upgrades

SRPT

Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform, Maintains Price Target to $80

Cibus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that its most recent trait for its herbicide tolerance trait (HT2) in Canola has been designated as "not regulated" by the United States Department of Agriculture's Animal and Plant Health Inspection Service (USDA-APHIS) Biotechnology Regulatory Services (BRS) as Plant Pests or Which There is Reason to Believe Are Plant Pests, as described in 7 CFR part 340.

CBUS

Cibus' Herbicide Tolerance Canola Trait HT2 Designated As Not Regulated Under USDA's Biotechnology Regulations

Citigroup analyst Eric Wolfe downgrades American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) from Buy to Neutral and maintains the price target from $41 to $41.

Downgrades

Citigroup Downgrades American Homes 4 Rent to Neutral, Maintains Price Target to $41

The Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) will release its first-quarter earnings results after the <a href="https://www.benzinga.com/quote/PLCE/earnings">closing bell on Friday, June 6.</a>
Analysts expect the Secaucus, New Jersey-based company to report quarterly loss at 51 cents per share. Children&#8217;s Place projects to report quarterly revenue at $260.62 million, compared to $267.88 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 11, the company reported that net sales for the fourth quarter fell 10.2% year-over-year to $408.6 million from $455.0 million in the year-ago period.
Children&#8217;s Place shares gained 3.6% to close at $6.59 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/plce/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>UBS analyst Jay Sole maintained a Neutral rating and cut the price target from $11 to $9 on March 4, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating with a price target of $9 on May 22, 2024. This analyst has an accuracy rate of 61%.</li>
<li>B. Riley Securities analyst Jeff Lick upgraded the stock from Sell to Neutral and cut the price target from $12 to $7 on April 24, 2024. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying PLCE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PLCE/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-1024x564.png" alt="" class="wp-image-940881" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06044033/image-86.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

PLCE

Children's Place Likely To Report Lower Q1 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

As of June 6, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Profrac Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, ProFrac Holding posted better-than-expected quarterly sales. &#8220;Our first quarter 2025 results were strong, with revenue increasing 32% and Adjusted EBITDA increasing 83% versus fourth quarter 2024. Further, we achieved new operating efficiency records both in terms of pump hours and average pump hours per fleet, a testament to our asset management program and execution in the field. In Proppant Production, volumes ramped significantly early in the quarter, and we achieved volumes in March that were the highest since November 2023,&#8221; said Matt Wilks, ProFrac&#8217;s Executive Chairman. The company's stock jumped around 89% over the past month and has a <a href="https://www.benzinga.com/quote/ACDC">52-week high of $9.49</a>.</li>
<li>RSI Value: 74.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ACDC Price Action: Shares of Profrac gained 10.7% to close at $8.63 on Thursday.</li>
<li>Edge Stock Ratings: 34.02 Momentum score with Value at 74.89. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/acdc"><img loading="lazy" decoding="async" width="406" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06072654/image-90.png" alt="" class="wp-image-941087" style="width:263px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06072654/image-90.png 406w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06072654/image-90-300x134.png 300w" sizes="(max-width: 406px) 100vw, 406px" /></a></figure>
<h3 class="wp-block-heading">Cool Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>)</h3>
<ul class="wp-block-list">
<li>On May 21, Cool Co posted better-than-expected first-quarter sales. Richard Tyrrell, CEO, said, "CoolCo had an active first quarter, marked by a vessel delivery, several vessels transitioning to new charters and dry-dockings all contributing to modestly higher quarter-on-quarter revenue. Two out of our 13 vessels were exposed to a challenging spot market during the period, as high LNG prices and extensive restocking activity drove cargos to Europe, putting downward pressure on ton-mile demand. Given these conditions, we were pleased to deliver the GAIL Sagar onto its long-term charter and secure term employment for an additional two vessels. Our results for the quarter reflect the one-off cost of positioning the GAIL Sagar, and we look forward to its full-quarter contribution starting in Q2." The company's stock gained around 15% over the past five days and <a href="https://www.benzinga.com/quote/CLCO">has a 52-week high</a> of $12.45.</li>
<li>RSI Value: 71.7</li>
<li>CLCO Price Action: Shares of Cool Company fell 0.3% to close at $7.00 on Thursday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

ACDC

CLCO

Top 2 Energy Stocks That May Fall Off A Cliff In Q2

Keybanc analyst Jackson Ader initiates coverage on Akamai Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Underweight rating and announces Price Target of $63.

AKAM

Keybanc Initiates Coverage On Akamai Technologies with Underweight Rating, Announces Price Target of $63

Citigroup analyst Eric Wolfe upgrades Invitation Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) from Neutral to Buy and raises the price target from $35 to $38.5.

INVH

Citigroup Upgrades Invitation Homes to Buy, Raises Price Target to $38.5

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Corey Tarlowe upgraded the rating for Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) from Underperform to Hold and raised the price target from $50 to $70. Urban Outfitters shares closed at $69.71 on Thursday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst David Anderson upgraded Ormat Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>) from Equal-Weight to Overweight and raised the price target from $80 to $86. Ormat Technologies shares closed at $75.12 on Thursday. <a href="https://www.benzinga.com/quote/ORA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying URBN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092241/image-98-1024x595.png" alt="" class="wp-image-941244" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092241/image-98-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092241/image-98-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092241/image-98-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06092241/image-98.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

URBN

This Urban Outfitters Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Friday

FOXX

Foxx Development Holdings To Be Included In Russell Microcap Index Following FTSE Russell's Preliminary 2025 Annual Reconstitution List

DTCK

Davis Commodities Announces Approval Of $30M Fundraising Plan To Establish Bitcoin Reserves To Strengthen Asset Allocation

Keybanc analyst Jackson Ader initiates coverage on Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Overweight rating and announces Price Target of $210.

Keybanc Initiates Coverage On Cloudflare with Overweight Rating, Announces Price Target of $210

Diana Shipping Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that through a separate wholly-owned subsidiary, it has entered into a time charter contract&nbsp;with Stone Shipping Ltd, for one of its Ice Class Panamax dry bulk vessels, the m/v Atalandi. The gross charter rate is US$9,000 per day for the first thirty-five (35) days of the charter period and US$10,100 per day for the balance period of the time charter, in each case minus a 5.00% commission paid to third parties, for a period until minimum June 15, 2026 up to maximum August 15, 2026. The charter is expected to commence on June 9, 2025.
The "Atalandi" is a 77,529 dwt Ice Class Panamax dry bulk vessel built in 2014.
The employment of "Atalandi" is anticipated to generate approximately US$3.62 million of gross revenue for the minimum scheduled period of the time charter.

Diana Shipping Enters Into Time Charter Contract With Stone Shipping For Ice Class Panamax Dry Bulk Vessel, m/v Atalandi

Press Releases

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care

Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

Hims & Hers Introduces 6-Month Wegovy® New Customer Offer

Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

RKLB

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hinge Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings

Needham

Piper Sandler

Citigroup

B of A Securities

Morgan Stanley

Stock,Market,And,Business,Activity,In,Asia.,Corporate,Value,And

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Emerging Markets

TSLA

LikeFolio&#39;s Watchlist (7 Stocks And 1 Crypto) During This Market Pullback

Screenshot 2024-09-04 at 5.36.44 PM

Biotech

General

MGRX

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Screenshot 2024-07-09 at 1.59.17 PM

Health Care

Erectile Function Vs Erectile Dysfunction: How MangoRx&#39;s (NASDAQ: MGRX) Product Sets Itself Apart And Caters To A Large Market (Pun Intended)

Comments

Hims & Hers Health

Noticias

Últimas noticias sobre Hims & Hers Health (NYSE:HIMS) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL